We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · October 21, 2021

Therapeutic-Dose Heparin for Thromboprophylaxis in High-Risk Hospitalized Patients With COVID-19

JAMA Internal Medicine

 

Additional Info

JAMA Internal Medicine
Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial
JAMA Intern Med 2021 Oct 07;[EPub Ahead of Print], AC Spyropoulos, M Goldin, D Giannis, W Diab, J Wang, S Khanijo, A Mignatti, E Gianos, M Cohen, G Sharifova, JM Lund, A Tafur, PA Lewis, KP Cohoon, H Rahman, CP Sison, ML Lesser, K Ochani, N Agrawal, J Hsia, VE Anderson, M Bonaca, JL Halperin, JI Weitz

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading